AstraZeneca has vowed to spend over $10 billion on R&D deals in Asia, focusing on China, amid ongoing fraud scandal ...
Inhibrx Biosciences, Inc. ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with two programs in clinical-stage development, today announced the departure of Dr. Brendan ...
A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.
Neal Shore, MD, FACS, discussed findings from the SunRISe-4 trial of TAR-200 and cetrelimab in muscle-invasive bladder cancer ...
News Medical on MSN23h
World first as MHRA approves trofolastat for diagnostic imaging of prostate cancer in menThe Medicines and Healthcare products Regulatory Agency (MHRA) has approved trofolastat (RoTecPSMA), the first prostate-specific membrane antigen (PSMA)-targeting product authorised for use with ...
Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) recently published two papers that advance the science of addressing critical issues with CAR T cell therapy in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback